SLC9A1 and neoplasm: Interestingly, specific clinical-approved inhibitors of Na+ influx (cariporide for NHE-1; and eslicarbazepine acetate for VGSCs) did not show effects on tumor [Na+], but the chemotherapeutic drug docetaxel did (James et al., 2022).